Economic evaluation of biosimilars for reimbursement purposes - what, when, how?
Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars. Objectives: We want to raise awareness of and explore methodological issues for the economic evaluation of biosimila...
Saved in:
Main Authors: | Evelien Moorkens (Author), Hannah Broux (Author), Isabelle Huys (Author), Arnold G. Vulto (Author), Steven Simoens (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020) -
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022) -
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
by: Yannick Vandenplas, et al.
Published: (2021)